



THE LILLY MDR-TB PARTNERSHIP AT-A-GLANCE

About: The Lilly MDR-TB Partnership was created to combat MDR-TB — a disease so daunting that no single organization can fight it alone. The Partnership is a public-private initiative that mobilizes 18 partners on five continents. These partners are some of the world’s most skilled and knowledgeable experts on the disease, with the experience to evaluate the condition from a 360-degree perspective.

Since 2003, The Partnership has worked to provide access to medicines, transfer manufacturing technology to the developing world, train healthcare workers, raise awareness and promote prevention and research, while providing support for communities and advocating on behalf of patients. Lilly is supporting the effort with \$135 million in donations, medications and technology to increase access to treatment and focus global resources on prevention and diagnosis and the treatment of patients with MDR-TB.

Financial Commitment: \$135 million U.S.

Country Reach: More than 50 countries

Program Elements:

- Community Support and Patient Advocacy
- Treatment, Training and Surveillance
- Transferring Technology
- Research
- Awareness and Prevention

Lilly MDR-TB Partners:

- Aspen Pharmacare, South Africa
- Eli Lilly and Company
- Harvard Medical School and Partners in Health (PIH)
- Hisun Pharmaceutical, China
- International Council of Nurses (ICN)
- International Federation of Red Cross and Red Crescent Societies (IFRC)
- International Hospital Federation (IHF)
- Purdue University, USA
- RESULTS Educational Fund
- Shasun Chemicals and Drugs, India
- SIA International/Biocom, Russia
- Stop TB Partnership
- TB Alert
- The Advocacy Partnership
- U.S. Centers for Disease Control and Prevention (CDC)
- World Economic Forum (WEF)
- World Health Organization (WHO)
- World Medical Association (WMA)